To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

Postoperative analgesia with liposomal bupivacaine vs. bupivacaine HCl in outpatient ACLR

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Author Verified
Ace Report Cover
September 2016

Postoperative analgesia with liposomal bupivacaine vs. bupivacaine HCl in outpatient ACLR

Vol: 5| Issue: 9| Number:29| ISSN#: 2564-2537
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Liposomal Bupivacaine for Pain Control After Anterior Cruciate Ligament Reconstruction: A Prospective, Double-Blinded, Randomized, Positive-Controlled Trial

Am J Sports Med. 2016 Jul;44(7):1680-6

Contributing Authors:
A Premkumar H Samady H Slone R Hash S Karas J Xerogeanes

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

32 patients scheduled for primary ACL reconstruction were randomized to periarticular injection of either liposomal bupivacaine or standard bupivacaine hydrochloride. The purpose of this study was to assess and compare analgesic efficacy between the two. Patients were assessed up to 6 days postoperatively. The results demonstrated no significant differences between groups in either pain scores ove...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.

Learn about our AI Driven
High Impact Search Feature

High Impact Icon

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.

Continue